Margaret Erdman
Psychiatric/Mental Health · West Allis, WINPI 1275836546
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 445 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 445 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Supernus Pharmaceuticals, Inc.$938
- Johnson & Johnson$844
- AbbVie$598
- Sunovion Pharmaceuticals Inc.$360
- Neurocrine Biosciences, Inc.$360
- plus $3K from 24 others
What the payments were for
- Food & beverage$7,06499%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 62 | $1,316 |
| Supernus Pharmaceuticals, Inc. | 69 | $938 |
| Johnson & Johnson | 58 | $844 |
| AbbVie | 57 | $598 |
| Sunovion Pharmaceuticals Inc. | 28 | $360 |
| Neurocrine Biosciences, Inc. | 20 | $360 |
| Vanda Pharmaceuticals Inc. | 16 | $330 |
| Axsome Therapeutics, Inc. | 17 | $329 |
| Otsuka America Pharmaceutical, Inc. | 19 | $328 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $299 |
| Teva Pharmaceuticals USA, Inc. | 9 | $204 |
| Harmony Biosciences LLC | 8 | $201 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $163 |
| Lundbeck LLC | 8 | $154 |
| Bausch Health US, LLC | 5 | $104 |
| Corium, LLC | 7 | $98 |
| OWP Pharmaceuticals, Inc. | 5 | $72 |
| Tris Pharma Inc | 3 | $56 |
| Indivior Inc. | 4 | $56 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $44 |
| Ironshore Pharmaceuticals Inc. | 3 | $43 |
| Noven Therapeutics, LLC | 2 | $40 |
| Lilly USA, LLC | 2 | $39 |
| Adlon Therapeutics L.p. | 2 | $29 |
| Eisai Inc. | 2 | $28 |
| Merck | 2 | $25 |
| Neuronetics, Inc. | 1 | $23 |
| Neos Therapeutics, LP | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,127 in reported general payments places this provider in the 95th percentile of 384 psychiatric/mental health providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 29 | $49,358 |
| VraylarCariprazine Hcl | 24 | $35,596 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $12,460 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $9,005 |
| Clozapine | 14 | $3,712 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 57 | $2,740 |
| Duloxetine Hcl | 40 | $1,317 |
| Bupropion Hcl | 28 | $560 |
| Propranolol Hcl | 30 | $526 |
| Gabapentin | 45 | $520 |
| Buspirone Hcl | 17 | $453 |
| Quetiapine Fumarate | 25 | $377 |
| Clonazepam | 34 | $366 |
| Fluoxetine Hcl | 99 | $290 |
| Bupropion XlBupropion Hcl | 28 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $328 | $49,35829 claims |
| AbbVieVraylar | $598 | $35,59624 claims |
| Axsome Therapeutics, Inc.Auvelity | $329 | $12,46011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $299 | $9,00523 claims |
| Lilly USA, LLCOlanzapine | $39 | $19111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 384 psychiatric/mental health providers in Wisconsin.
Other psychiatric/mental health in West Allis
- Susan ChapmanWest Allis$4K
- Carolyn DavidsonMilwaukee$46K
- Sherry AleksichMilwaukee$33K
- Bobbi DurstPewaukee$23K
- Ngozi ObioraMilwaukee$19K
- Glenda McConnellGreen Bay$14K
- Debra BenishekGreen Bay$12K
- Shalonda MylesBrown Deer$12K
- Victoria McGinleyMilwaukee$9K
- Janet BurnsBrookfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.